264 related articles for article (PubMed ID: 33413835)
21. Comparison of clinical characteristics of real-life atrial fibrillation patients treated with vitamin K antagonists, dabigatran, and rivaroxaban: results from the CRAFT study.
Balsam P; Ozierański K; Tymińska A; Żukowska K; Zaleska M; Szepietowska K; Maciejewski K; Peller M; Grabowski M; Lodziński P; Praska-Ogińska A; Zaboyska I; Kołtowski Ł; Kowalczuk A; Bednarski J; Filipiak KJ; Opolski G
Kardiol Pol; 2018; 76(5):889-898. PubMed ID: 29350386
[TBL] [Abstract][Full Text] [Related]
22. Non-vitamin K antagonist oral anticoagulants in very elderly east Asians with atrial fibrillation: A nationwide population-based study.
Kwon S; Lee SR; Choi EK; Choe WS; Lee E; Jung JH; Han KD; Oh S; Lip GYH
Am Heart J; 2020 Nov; 229():81-91. PubMed ID: 32927313
[TBL] [Abstract][Full Text] [Related]
23. Non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients without previous oral anticoagulants or stable under warfarin: a nationwide cohort study.
Liu SH; Chao TF; Chan YH; Liao JN; Chen TJ; Lip GYH; Chen SA
Europace; 2023 May; 25(5):. PubMed ID: 37144590
[TBL] [Abstract][Full Text] [Related]
24. Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention oF thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF).
Rohla M; Weiss TW; Pecen L; Patti G; Siller-Matula JM; Schnabel RB; Schilling R; Kotecha D; Lucerna M; Huber K; De Caterina R; Kirchhof P
BMJ Open; 2019 Mar; 9(3):e022478. PubMed ID: 30928922
[TBL] [Abstract][Full Text] [Related]
25. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
Cheng JW; Barillari G
J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
[TBL] [Abstract][Full Text] [Related]
26. Underuse of oral anticoagulants in privately insured patients with atrial fibrillation: A population being targeted by the IMplementation of a randomized controlled trial to imProve treatment with oral AntiCoagulanTs in patients with Atrial Fibrillation (IMPACT-AFib).
Al-Khatib SM; Pokorney SD; Al-Khalidi HR; Haynes K; Garcia C; Martin D; Goldsack JC; Harkins T; Cocoros NM; Lin ND; Lipowicz H; McCall D; Nair V; Parlett L; McMahill-Walraven CN; Platt R; Granger CB
Am Heart J; 2020 Nov; 229():110-117. PubMed ID: 32949986
[TBL] [Abstract][Full Text] [Related]
27. Improved Stroke Prevention in Atrial Fibrillation After the Introduction of Non-Vitamin K Antagonist Oral Anticoagulants.
Forslund T; Komen JJ; Andersen M; Wettermark B; von Euler M; Mantel-Teeuwisse AK; Braunschweig F; Hjemdahl P
Stroke; 2018 Sep; 49(9):2122-2128. PubMed ID: 30354995
[TBL] [Abstract][Full Text] [Related]
28. Contemporary stroke prevention strategies in 11 096 European patients with atrial fibrillation: a report from the EURObservational Research Programme on Atrial Fibrillation (EORP-AF) Long-Term General Registry.
Boriani G; Proietti M; Laroche C; Fauchier L; Marin F; Nabauer M; Potpara T; Dan GA; Kalarus Z; Diemberger I; Tavazzi L; Maggioni AP; Lip GYH; ;
Europace; 2018 May; 20(5):747-757. PubMed ID: 29016832
[TBL] [Abstract][Full Text] [Related]
29. Risk of major bleeding and stroke associated with the use of vitamin K antagonists, nonvitamin K antagonist oral anticoagulants and aspirin in patients with atrial fibrillation: a cohort study.
Gieling EM; van den Ham HA; van Onzenoort H; Bos J; Kramers C; de Boer A; de Vries F; Burden AM
Br J Clin Pharmacol; 2017 Aug; 83(8):1844-1859. PubMed ID: 28205318
[TBL] [Abstract][Full Text] [Related]
30. Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Cancer and Atrial Fibrillation: A Systematic Review and Meta-Analysis.
Deng Y; Tong Y; Deng Y; Zou L; Li S; Chen H
J Am Heart Assoc; 2019 Jul; 8(14):e012540. PubMed ID: 31310583
[TBL] [Abstract][Full Text] [Related]
31. Use of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients: insights from a specialist atrial fibrillation clinic.
Lee SI; Sayers M; Lip GY; Lane DA
Int J Clin Pract; 2015 Nov; 69(11):1341-8. PubMed ID: 26234557
[TBL] [Abstract][Full Text] [Related]
32. Prognostic implications of adherence to oral anticoagulants among patients with atrial fibrillation: Insights from MISOAC-AF trial.
Patsiou V; Samaras A; Kartas A; Moysidis DV; Papazoglou AS; Bekiaridou A; Baroutidou A; Ziakas A; Tzikas A; Giannakoulas G
J Cardiol; 2023 Apr; 81(4):390-396. PubMed ID: 36179772
[TBL] [Abstract][Full Text] [Related]
33. Trends and Variation in Oral Anticoagulant Choice in Patients with Atrial Fibrillation, 2010-2017.
Zhu J; Alexander GC; Nazarian S; Segal JB; Wu AW
Pharmacotherapy; 2018 Sep; 38(9):907-920. PubMed ID: 29920705
[TBL] [Abstract][Full Text] [Related]
34. Causes and Risk Factors of Cerebral Ischemic Events in Patients With Atrial Fibrillation Treated With Non-Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention.
Paciaroni M; Agnelli G; Caso V; Silvestrelli G; Seiffge DJ; Engelter S; De Marchis GM; Polymeris A; Zedde ML; Yaghi S; Michel P; Eskandari A; Antonenko K; Sohn SI; Cappellari M; Tassinari T; Tassi R; Masotti L; Katsanos AH; Giannopoulos S; Acciarresi M; Alberti A; Venti M; Mosconi MG; Vedovati MC; Pierini P; Giustozzi M; Lotti EM; Ntaios G; Kargiotis O; Monaco S; Lochner P; Bandini F; Liantinioti C; Palaiodimou L; Abdul-Rahim AH; Lees K; Mancuso M; Pantoni L; Rosa S; Bertora P; Galliazzo S; Ageno W; Toso E; Angelini F; Chiti A; Orlandi G; Denti L; Flomin Y; Marcheselli S; Mumoli N; Rimoldi A; Verrengia E; Schirinzi E; Del Sette M; Papamichalis P; Komnos A; Popovic N; Zarkov M; Rocco A; Diomedi M; Giorli E; Ciccone A; Mac Grory BC; Furie KL; Bonetti B; Saia V; Guideri F; Acampa M; Martini G; Grifoni E; Padroni M; Karagkiozi E; Perlepe K; Makaritsis K; Mannino M; Maccarrone M; Ulivi L; Giannini N; Ferrari E; Pezzini A; Doronin B; Volodina V; Baldi A; D'Amore C; Deleu D; Corea F; Putaala J; Santalucia P; Nardi K; Risitano A; Toni D; Tsivgoulis G
Stroke; 2019 Aug; 50(8):2168-2174. PubMed ID: 31234756
[TBL] [Abstract][Full Text] [Related]
35. Age Threshold for Increased Stroke Risk Among Patients With Atrial Fibrillation: A Nationwide Cohort Study From Taiwan.
Chao TF; Wang KL; Liu CJ; Lin YJ; Chang SL; Lo LW; Hu YF; Tuan TC; Chung FP; Liao JN; Chen TJ; Chiang CE; Lip GY; Chen SA
J Am Coll Cardiol; 2015 Sep; 66(12):1339-47. PubMed ID: 26383720
[TBL] [Abstract][Full Text] [Related]
36. Use of oral anticoagulants after ischaemic stroke in patients with atrial fibrillation and cancer.
Atterman A; Asplund K; Friberg L; Engdahl J
J Intern Med; 2020 Oct; 288(4):457-468. PubMed ID: 32386073
[TBL] [Abstract][Full Text] [Related]
37. Association of Intracerebral Hemorrhage Among Patients Taking Non-Vitamin K Antagonist vs Vitamin K Antagonist Oral Anticoagulants With In-Hospital Mortality.
Inohara T; Xian Y; Liang L; Matsouaka RA; Saver JL; Smith EE; Schwamm LH; Reeves MJ; Hernandez AF; Bhatt DL; Peterson ED; Fonarow GC
JAMA; 2018 Feb; 319(5):463-473. PubMed ID: 29372247
[TBL] [Abstract][Full Text] [Related]
38. Oral Anticoagulant Use for Patients with Atrial Fibrillation with Concomitant Anemia and/or Thrombocytopenia.
Yeh YH; Chan YH; Chen SW; Chang SH; Wang CL; Kuo CT; Lip GYH; Chen SA; Chao TF
Am J Med; 2022 Aug; 135(8):e248-e256. PubMed ID: 35381212
[TBL] [Abstract][Full Text] [Related]
39. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH
Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628
[TBL] [Abstract][Full Text] [Related]
40. Oral anticoagulation therapy use in patients with atrial fibrillation after the introduction of non-vitamin K antagonist oral anticoagulants: findings from the French healthcare databases, 2011-2016.
Maura G; Billionnet C; Drouin J; Weill A; Neumann A; Pariente A
BMJ Open; 2019 Apr; 9(4):e026645. PubMed ID: 31005934
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
